A Case of Advanced Biliary Tract Cancer With EGFR Amplification That Responded to Necitumumab.

ABSTRACT:

Background

Recent advances in cancer genome analysis and the practice of precision medicine have made it possible to identify fractions with rare genetic alterations. Among biliary tract cancers, EGFR-amplified cancers are known to be rare fractions across organs and have a poor prognosis. The use of anti-EGFR antibody for EGFR-amplified cancers has been promising; however, the evidence is not yet clear.

Case

In this report, we describe the case of a 48-year-old man diagnosed with advanced gallbladder cancer. The patient was administered gemcitabine plus cisplatin, followed by S-1 monotherapy; however, disease progression was observed after two cycles of each regimen. Comprehensive genomic profiling test revealed EGFR-amplification, and the patient was treated with combinati

SUBMITTER: Sugimori M 

PROVIDER: S-EPMC11561843 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature